Curriculum
Module 13 · 35 min
Cognitive & Nootropic Peptides
Semax, Selank, Cerebrolysin, Dihexa, Cerebrolysin, NSI-189-style claims.
ClinicalAdvanced
Core topics
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
Learning objectives
By the end of this module you will be able to
- L01State the regulatory status of semax, selank, cerebrolysin in the US vs Russia/EU.
- L02Critique a 'nootropic peptide' claim.
Expected takeaways
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
Takeaway mastery
0 / 1 · 0%
A takeaway counts as mastered when you score ≥80% on its self-check.
Lesson · Core emphasis
What this means for you
Patient summary
Several 'brain peptides' are licensed in Russia or central Europe but not in the US, and Western evidence is thin. Be skeptical of online vendor claims.
Clinician summary
Cerebrolysin: meta-analyses in ischemic stroke show modest benefit on disability scores; not US-approved.
Evidence-graded claims
What the data say
C
Cerebrolysin improves recovery after acute ischemic stroke
Meta-analyses suggest modest signal; heterogeneous trials.
F
Dihexa is a safe nootropic for healthy adults
No human safety data.
Quick check
Test yourself
Q1US regulatory status of Cerebrolysin?
Flashcards · Spaced repetition
Lock it in — review what's due
Due1Total1
FrontNew
1 in queueWhat is Cerebrolysin?
Click to reveal answer
References · 2
Sources cited in this module
- [1]Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialMuresanu DF. et al. · Stroke · 2016RCT · T2
- [2]Semax, an analog of ACTH(4–10): pharmacological properties and clinical applicationsKolomin T. et al. · Current Drug Metabolism · 2013Review · T3